Delwedd Flaen

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections

Kellie J Goodlet,1 David P Nicolau,2 Michael D Nailor1,3 1Department of Pharmacy Services, Hartford Hospital, Hartford, CT, USA; 2Center of Anti-Infective Research, Hartford Hospital, Hartford, CT, USA; 3Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, CT, USA...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awduron:	Goodlet KJ (Awdur), Nicolau DP (Awdur), Nailor MD (Awdur)
Fformat:	Llyfr
Cyhoeddwyd:	Dove Medical Press, 2016-12-01T00:00:00Z.
Pynciau:	article
Mynediad Ar-lein:	Connect to this object online.
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
gan: Skalweit MJ
Cyhoeddwyd: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
gan: Giancola SE, et al.
Cyhoeddwyd: (2016)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
gan: Marianna Criscuolo, et al.
Cyhoeddwyd: (2020)

Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
gan: Wasim S. El Nekidy, et al.
Cyhoeddwyd: (2024)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
gan: Rosario Cultrera, et al.
Cyhoeddwyd: (2020)

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam
gan: Jade L. L. Teng, et al.
Cyhoeddwyd: (2024)

Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice
gan: Bryan Hausman, et al.
Cyhoeddwyd: (2024)

Ceftolozane/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals
gan: Anis Karuniawati, et al.
Cyhoeddwyd: (2022)

Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
gan: Hidalgo JA, et al.
Cyhoeddwyd: (2016)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
gan: María José Contreras-Gómez, et al.
Cyhoeddwyd: (2022)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
gan: Arhodoula Papadomanolaki, et al.
Cyhoeddwyd: (2022)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
gan: Marco Fiore, et al.
Cyhoeddwyd: (2021)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
gan: Fabián Hernández
Cyhoeddwyd: (2020)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
gan: Venere Cortazzo, et al.
Cyhoeddwyd: (2022)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
gan: Jesus Ruiz, et al.
Cyhoeddwyd: (2020)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
gan: Jan Thomas De Pourcq, et al.
Cyhoeddwyd: (2024)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
gan: Marianna Meschiari, et al.
Cyhoeddwyd: (2021)

Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China
gan: Xiaoping Shi, et al.
Cyhoeddwyd: (2023)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
gan: Joseph Terracciano, PhD, et al.
Cyhoeddwyd: (2017)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
gan: Z. S. Khankhel, et al.
Cyhoeddwyd: (2022)

Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children
gan: Zhu L, et al.
Cyhoeddwyd: (2024)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
gan: Li-Ting Wang, et al.
Cyhoeddwyd: (2021)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
gan: Marco Fiore, et al.
Cyhoeddwyd: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
gan: George L. Daikos, et al.
Cyhoeddwyd: (2021)

Analysis of the clinical application of ceftazidime-avibactam in China
gan: Qing Wang, et al.
Cyhoeddwyd: (2022)

Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
gan: Xing Tan, et al.
Cyhoeddwyd: (2019)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
gan: Mario Pezzi, et al.
Cyhoeddwyd: (2019)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
gan: Wei Yu, et al.
Cyhoeddwyd: (2021)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
gan: Marta Palombo, et al.
Cyhoeddwyd: (2023)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
gan: Dan Li, et al.
Cyhoeddwyd: (2021)

Ceftazidime-avibactam induced renal disorders: past and present
gan: Yanrong Shi, et al.
Cyhoeddwyd: (2024)

Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia
gan: Abdullah Algwizani, et al.
Cyhoeddwyd: (2018)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
gan: Laura Butragueño-Laiseca, et al.
Cyhoeddwyd: (2020)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
gan: Marta Palombo, et al.
Cyhoeddwyd: (2023)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
gan: Alessandro Mancuso, et al.
Cyhoeddwyd: (2023)

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
gan: Wenqiang Kong, et al.
Cyhoeddwyd: (2023)

Efficacy and Safety of Ceftazidime-Avibactam Alone versus Ceftazidime-Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort
gan: Marco Fois, et al.
Cyhoeddwyd: (2024)

Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
gan: Maria Di Pietrantonio, et al.
Cyhoeddwyd: (2022)

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria
gan: S. V. Nedogoda, et al.
Cyhoeddwyd: (2019)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
gan: Dai Y, et al.
Cyhoeddwyd: (2021)